Core Viewpoint - Multiple listed companies have announced new share buyback plans, signaling confidence in the market and aiming to enhance investor trust [1][2][3] Group 1: Share Buyback Plans - Over 10 listed companies, including COSCO Shipping Holdings, Aibee, and Jiuan Medical, have released announcements regarding share buybacks in the four trading days following the National Day holiday [1] - COSCO Shipping Holdings plans to repurchase between 50 million to 100 million A-shares at a maximum price of 14.98 yuan per share, with a total fund limit of 1.498 billion yuan [2] - Jiuan Medical has set a buyback fund total of 300 million to 600 million yuan, with a special loan commitment of up to 500 million yuan from Shanghai Pudong Development Bank [3] Group 2: Characteristics of Buybacks - The current buyback trend shows two main characteristics: many companies are frequent buyers, launching multiple buyback plans within a year, and the execution efficiency of these buybacks is notably high [4][5] - COSCO Shipping Holdings has initiated its third round of A+H share buybacks since last October, having repurchased a total of 152 million A-shares for 2.146 billion yuan in previous rounds [4] - Aibee has also demonstrated a high frequency of buybacks, completing a plan in January and announcing further buybacks in April and October, with total funds ranging from 20 million to 50 million yuan [4] Group 3: Efficient Execution - Companies like Huaxin Cement and China International Marine Containers have shown rapid execution of their buyback plans, with Huaxin Cement completing its first buyback within a day of announcing it [6] - Huaxin Cement's buyback plan involved using self-owned funds to repurchase A-shares for a total amount between 32.25 million and 64.5 million yuan, completing the buyback of 1.5572 million shares for approximately 28.09 million yuan [6] - China International Marine Containers quickly repurchased 241,080 A-shares using nearly 20 million yuan shortly after announcing its buyback plan [6]

Core Viewpoint - The company emphasizes the importance of market value management, focusing on core business operations and investor interests while maintaining a balance between intrinsic and market value [1] Group 1: Market Value Management - The company is committed to optimizing corporate governance and enhancing operational quality to improve market value [1] - It aims to strengthen information disclosure and investor communication as part of its market value management strategy [1] - The company plans to utilize tools such as cash dividends, stock transfers, and equity incentives to support its market value management efforts [1] Group 2: Shareholder Interests - The company is dedicated to safeguarding the long-term interests of all shareholders through its market value management initiatives [1] - Any plans for stock buybacks or increases will be disclosed in accordance with relevant information disclosure regulations [1]

（文章来源：证券日报） 证券日报网讯华润三九10月14日在互动平台回答投资者提问时表示，公司高度重视市值管理工作，围绕 公司发展战略，聚焦主业发展，持续提升公司核心竞争力，重视股东回报，持续现金分红，努力推动高 质量发展。公司如有相关计划，将严格按照监管要求履行信息披露义务。 ...

证券日报网讯中海达（300177）10月14日在互动平台回答投资者提问时表示，公司重视市值管理工作， 在贯彻和落实上市公司市值管理的相关规定下，公司坚持合法合规稳健经营，努力提升公司的投资价 值。 ...

Group 1 - The company actively responds to the policies and guidelines on market value management issued by the State-owned Assets Supervision and Administration Commission and the China Securities Regulatory Commission [1] - The company is formulating reasonable development strategies and corresponding operational plans to promote healthy operations and sustainable development [1] - The company is enhancing investor relations management and improving the quality of information disclosure to effectively manage market value [1]

Group 1 - The core point of the news is that Zhonggong International (002051.SZ) announced a share buyback plan to demonstrate confidence in its future development and recognition of its own value, aiming to protect shareholder interests and enhance company value [1] - The buyback will target the company's ordinary shares (A-shares) at a price not exceeding 12.85 RMB per share, with a total buyback fund of 50 million to 100 million RMB, representing approximately 0.31% to 0.63% of the current total share capital [1] - The shares repurchased will be used for cancellation to reduce the registered capital, with a buyback period of 12 months following the approval of the plan by the shareholders' meeting [1] Group 2 - In February 2025, Zhonggong International introduced a market value management system focused on value creation, with the buyback being a reflection of its long-term commitment to market value management [2] - The company emphasizes enhancing the quality of listed companies and maintains a high dividend policy of at least 40% of distributable profits, alongside solid information disclosure practices [2] - The chairman of the group highlighted the importance of improving investment value and investor returns as a long-term focus, encouraging listed companies to effectively utilize market value management tools [2] Group 3 - From a long-term development perspective, the buyback aligns closely with Zhonggong International's strategic planning, aiming to maintain its goal of becoming a "technology-driven professional engineering company" [3] - The company plans to enhance its core competitiveness across the entire engineering industry chain and focus on high-end value chains and technological innovation [3] - The buyback serves as a direct endorsement of the company's clear development path and is expected to boost market confidence, facilitating the return of company value and promoting high-quality development [3]

Group 1 - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share, to maintain company value and shareholder rights [1] - The current share price of 38.19 yuan represents a discount of approximately 28% compared to the repurchase cap, signaling potential valuation recovery [1] - The repurchased shares are intended to be sold within 12 months after the announcement, providing short-term price stability and future funding flexibility for business transformation [1] Group 2 - Lingbei's drug Bexicaserin has been recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) in China for treating developmental epileptic encephalopathy (DEE) [2] - Bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce cardiovascular risks, marking a significant milestone in Lingbei's development in China [2] Group 3 - Four Rings Pharmaceutical has announced an investment in Swiss medical aesthetics company Suisselle SA, strengthening their long-term partnership [3] - This investment allows Four Rings to maintain exclusive rights to the CELLBOOSTER® product in China and participate deeply in its operations and development [3] - The collaboration aims to accelerate the promotion and sales of Four Rings' self-developed aesthetic products in Europe and other overseas markets [3] Group 4 - Fudan Zhangjiang's application for the drug Obechol acid tablets for treating primary biliary cholangitis was not approved by the NMPA due to non-compliance with registration requirements [4] - The project has incurred approximately 125 million yuan in R&D investment, which will not significantly impact the company's current financial status [4] - The company needs to review the reasons for the rejection and optimize its pipeline to enhance future R&D efficiency [4] Group 5 - Sunshine Nuohuo's BTP4507 has received approval for clinical trials from the NMPA, targeting primary hypertension patients with inadequate response to monotherapy [5] - BTP4507 is a compound formulation designed to address multiple hypertension targets, catering to the needs of over 300 million hypertensive patients in China [5] - If successful in clinical trials, this drug could open new growth avenues for the company, although it will face competition from similar combination therapies [5]

Group 1 - The company will hold its third extraordinary general meeting of shareholders in 2025 on October 30, 2025, at 14:30 [2][5] - The meeting will be convened by the board of directors, and the voting method will combine on-site and online voting [2][3] - The on-site meeting will take place at the Big Data Technology Park, Fuzhou, Fujian Province [2][3] Group 2 - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [3][4] - Shareholders can vote through designated trading securities company terminals or the internet voting platform [7][10] - The company has confirmed that there are no special resolutions or related party voting issues for this meeting [7][10] Group 3 - The meeting will allow shareholders registered by the close of trading on the registration date to attend and vote [10][12] - Shareholders can appoint proxies to attend the meeting, and the proxy does not need to be a shareholder [10][12] - Registration for attendance does not constitute a prerequisite for shareholders to participate in the meeting [14]

Core Viewpoint - The company emphasizes the importance of market value management and focuses on its core business development to enhance its competitive edge [1] Group 1 - The company is committed to ensuring the safety of its funds while engaging in cash management to improve capital efficiency and generate investment returns [1] - Currently, the company has not initiated employee stock ownership plans or buybacks, and any future actions will be disclosed in accordance with information disclosure regulations [1]

Core Viewpoint - The company emphasizes the importance of market value management and is committed to enhancing its value through improved operations and investor relations [1] Group 1: Company Initiatives - The company has been focusing on improving the quality of the listed company and enhancing the quality of information disclosure [1] - The company is strengthening investor relations management and ensuring compliance with regulations [1] - The company aims to continuously improve its operational management to enhance performance and intrinsic value [1]